A novel role for tumor necrosis factor-α in regulating susceptibility of activated CD4+ T cells from human and nonhuman primates for distinct coreceptor using lentiviruses

Although CD4+ T-cell activation has long been shown to promote infection and replication of simian immunodeficiency virus (SIV) and HIV, recent studies have documented that not all activated CD4+ T cells from human and nonhuman primates are susceptible to infection with HIV/SIV, respectively. Activation of CD4+ T cells with anti-CD3 + anti-CD28 conjugated beads led to induction of a state of anti-viral resistance to infection with strains of viruses that primarily use CCR5 as a coreceptor. The studies reported herein were designed to address the mechanism by which anti-CD3 + anti-CD28-induced stimulation in turn induced antiviral resistance. Results of these studies show that the anti-viral resistance induced by activation of CD4+ T cells with anti-CD3 + anti-CD28 is primarily conferred by the synthesis of tumor necrosis factor-alpha (TNF-alpha), and highlight a unique regulatory role for TNF-alpha in regulating synthesis of MIP-1alpha, MIP-1beta, and regulated-on-activation normal T-expressed and secreted cells, which contributes to this state of antiviral resistance to R5-tropic strains of HIV/SIV. However, while TNF-alpha has a protective role in antiviral resistance of activated CD4+ T cells to R5-tropic viruses, it enhances CXCR4 expression of CD4+ T cells and mediates increased susceptibility to infection with X4-tropic strains of HIV and recombinant SIVs. The results of the studies reported herein also suggest that it is not the Th1 v/s Th2 cytokine profile but the mode of CD4+ T-cell activation that dictates the synthesis of distinct cytokines which regulate the expression of chemokines and chemokine receptors which in turn regulate and confer susceptibility/resistance to R5 v/s X4-tropic HIV and SIV.

[1]  H. Schuitemaker,et al.  CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. , 1999, Journal of immunology.

[2]  D. Markovitz,et al.  TNF-alpha inhibits HIV-1 replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing C-C chemokine receptor 5 (CCR5) expression. , 1999, Journal of immunology.

[3]  R. Hengel,et al.  Markers of lymphocyte homing distinguish CD4 T cell subsets that turn over in response to HIV-1 infection in humans. , 1999, Journal of immunology.

[4]  J. Hoxie,et al.  Inhibitory Mechanism of the CXCR4 Antagonist T22 against Human Immunodeficiency Virus Type 1 Infection , 1999, Journal of Virology.

[5]  J. Levy,et al.  Sensitivity of human immunodeficiency virus infection to various alpha, beta and gamma chemokines. , 1999, The Journal of general virology.

[6]  E. Vicenzi,et al.  Envelope-Dependent Restriction of Human Immunodeficiency Virus Type 1 Spreading in CD4+ T Lymphocytes: R5 but Not X4 Viruses Replicate in the Absence of T-Cell Receptor Restimulation , 1999, Journal of Virology.

[7]  Poli Laureate ESCI award for excellence in clinical science 1999 Cytokines and the human immunodeficiency virus: from bench to bedside , 1999, European journal of clinical investigation.

[8]  Anthony S. Fauci,et al.  Both Memory and CD45RA+/CD62L+ Naive CD4+ T Cells Are Infected in Human Immunodeficiency Virus Type 1-Infected Individuals , 1999, Journal of Virology.

[9]  F. Belardelli,et al.  Human Immunodeficiency Virus Type 1 Strains R5 and X4 Induce Different Pathogenic Effects in hu-PBL-SCID Mice, Depending on the State of Activation/Differentiation of Human Target Cells at the Time of Primary Infection , 1999, Journal of Virology.

[10]  M. Emerman,et al.  Cell Cycle- and Vpr-Mediated Regulation of Human Immunodeficiency Virus Type 1 Expression in Primary and Transformed T-Cell Lines , 1999, Journal of Virology.

[11]  Q. Sattentau,et al.  Constitutive cell surface association between CD4 and CCR5. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Hoxie,et al.  Determinant in Human Immunodeficiency Virus Type 1 for Efficient Replication under Cytokine-Induced CD4+ T-Helper 1 (Th1)- and Th2-Type Conditions , 1999, Journal of Virology.

[13]  C. Boucher,et al.  Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. , 1998, The Journal of infectious diseases.

[14]  C. Hillyer,et al.  Development of an animal model for autotransfusion therapy: in vitro characterization and analysis of anti-CD3/CD28 expanded cells. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[15]  Rey,et al.  Evidence for a role of T‐helper type 2 cytokines in the acquisition of human immunodeficiency virus syncytium‐inducing phenotype , 1998, European journal of clinical investigation.

[16]  S. Spector,et al.  Human Immunodeficiency Virus Type 1 Induction Mediated by Genistein Is Linked to Cell Cycle Arrest in G2 , 1998, Journal of Virology.

[17]  B. Levine,et al.  Naı̈ve and Memory CD4 T Cells Differ in Their Susceptibilities to Human Immunodeficiency Virus Type 1 Infection following CD28 Costimulation: Implications for Transmission and Pathogenesis , 1998, Journal of Virology.

[18]  L. Cosmi,et al.  Enhanced HIV expression during Th2‐oriented responses explained by the opposite regulatory effect of IL‐4 and IFN‐γ on fusin/CXCR4 , 1998, European journal of immunology.

[19]  T. Oravecz,et al.  Cytokine Regulation of Human Immunodeficiency Virus Type 1 Entry and Replication in Human Monocytes/Macrophages through Modulation of CCR5 Expression , 1998, Journal of Virology.

[20]  C. Cheng‐Mayer,et al.  Mucosal transmission of pathogenic CXCR4-utilizing SHIVSF33A variants in rhesus macaques. , 1998, Virology.

[21]  J. Albert,et al.  Dual effect of interleukin 4 on HIV-1 expression: implications for viral phenotypic switch and disease progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  K. Ikuta,et al.  Dependence on host cell cycle for activation of human immunodeficiency virus type 1 gene expression from latency. , 1998, The Journal of general virology.

[23]  J. Bousquet,et al.  Cutting Edge: IL-4 Induces Functional Cell-Surface Expression of CXCR4 on Human T Cells , 1998, The Journal of Immunology.

[24]  M. Pope,et al.  Dendritic cells from skin and blood of macaques both promote SIV replication with T cells from different anatomical sites , 1998, Journal of medical primatology.

[25]  C. Hillyer,et al.  Expression and in vitro evaluation of rhesus macaque wild type (wt) and modified CC chemokines , 1998, Journal of medical primatology.

[26]  Y. Korin,et al.  Progression to the G1b Phase of the Cell Cycle Is Required for Completion of Human Immunodeficiency Virus Type 1 Reverse Transcription in T Cells , 1998, Journal of Virology.

[27]  C. Mackay,et al.  Flexible Programs of Chemokine Receptor Expression on Human Polarized T Helper 1 and 2 Lymphocytes , 1998, The Journal of experimental medicine.

[28]  E. Kremmer,et al.  Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation. , 1998, Journal of immunology.

[29]  P. Allavena,et al.  Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s , 1998, The Journal of experimental medicine.

[30]  R. Doms,et al.  A Small-molecule Inhibitor Directed against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor , 1997, The Journal of experimental medicine.

[31]  E. Clercq,et al.  Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4 , 1997, The Journal of experimental medicine.

[32]  N. Yoshida,et al.  A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line–tropic HIV-1 Infection , 1997, The Journal of experimental medicine.

[33]  Q. Sattentau,et al.  HIV-1 gp120 induces an association between CD4 and the chemokine receptor CXCR4. , 1997, Journal of immunology.

[34]  B. Levine,et al.  Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 costimulation. , 1997, Journal of immunology.

[35]  B. Levine,et al.  Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. , 1997, Science.

[36]  T. Schwartz,et al.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.

[37]  C. Mackay,et al.  The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  C. Hillyer,et al.  Immune and hematopoietic parameters in HIV‐1‐infected chimpanzees during clinical progression toward AIDS , 1997, Journal of medical primatology.

[39]  E. Clark,et al.  Nuclear import of HIV-1 DNA in resting CD4+ T cells requires a cyclosporin A-sensitive pathway. , 1997, Journal of immunology.

[40]  P. Zipfel,et al.  Synthesis of the CC-chemokines MIP-1alpha, MIP-1beta, and RANTES is associated with a type 1 immune response. , 1996, Journal of immunology.

[41]  M. Baggiolini,et al.  HIV blocked by chemokine antagonist , 1996, Nature.

[42]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[43]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[44]  D. Littman,et al.  Natural resistance to HIV? , 1996, Nature.

[45]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[46]  M. Baggiolini,et al.  Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes , 1996, The Journal of experimental medicine.

[47]  Marc Parmentier,et al.  A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.

[48]  Ying Sun,et al.  The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.

[49]  C. Broder,et al.  CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.

[50]  Bruce L. Levine,et al.  Antiviral Effect and Ex Vivo CD4+ T Cell Proliferation in HIV-Positive Patients as a Result of CD28 Costimulation , 1996, Science.

[51]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[52]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[53]  H. Schuitemaker,et al.  Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. , 1996, The Journal of infectious diseases.

[54]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[55]  E. Clark,et al.  Formation of simian immunodeficiency virus long terminal repeat circles in resting T cells requires both T cell receptor- and IL-2-dependent activation , 1995, The Journal of experimental medicine.

[56]  J. Levy,et al.  CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[57]  T. Schall,et al.  Regulation of the production of the RANTES chemokine by endothelial cells. Synergistic induction by IFN-gamma plus TNF-alpha and inhibition by IL-4 and IL-13. , 1995, Journal of immunology.

[58]  D. Ho,et al.  Effect of different donor cells on human immunodeficiency virus type 1 replication and selection in vitro , 1995, Journal of virology.

[59]  M. Roos,et al.  Immunological and virological markers determining progression to AIDS. , 1994, Netherlands Journal of Medicine.

[60]  D. Richman,et al.  The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. , 1994, The Journal of infectious diseases.

[61]  B. Chesebro,et al.  Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1 , 1994, Journal of virology.

[62]  J. Albert,et al.  MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection , 1994, Journal of clinical microbiology.

[63]  E. Clark,et al.  T-cell activation influences initial DNA synthesis of simian immunodeficiency virus in resting T lymphocytes from macaques , 1993, Journal of virology.

[64]  I. Keet,et al.  Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS , 1993, Annals of Internal Medicine.

[65]  K. Sell,et al.  Inhibition of cellular activation of retroviral replication by CD8+ T cells derived from non‐human primates , 1993, Clinical and experimental immunology.

[66]  D. Venzon,et al.  Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. , 1993, The Journal of clinical investigation.

[67]  H. Schuitemaker,et al.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.

[68]  C. Cheng‐Mayer,et al.  Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation , 1990, Journal of virology.

[69]  G. Gaudernack,et al.  CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence for a soluble inhibitor. , 1990, Journal of immunology.

[70]  G. Soma,et al.  AUGMENTATION OF IN-VITRO HIV REPLICATION IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF AIDS AND ARC PATIENTS BY TUMOUR NECROSIS FACTOR , 1989, The Lancet.

[71]  Lange,et al.  Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates , 1989, Journal of virology.

[72]  J. Albert,et al.  Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates , 1988, Journal of virology.

[73]  C. Maury,et al.  Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. , 1988, The American journal of medicine.

[74]  Huisman,et al.  Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex , 1988, Journal of virology.

[75]  N. Letvin,et al.  Suppression of simian immunodeficiency virus replication in vitro by CD8+ lymphocytes. , 1988, Journal of immunology.

[76]  Q. Sattentau,et al.  The CD4 antigen: Physiological ligand and HIV receptor , 1988, Cell.

[77]  M. Wainberg,et al.  Differential susceptibility of human lymphocyte cultures to infection by HIV. , 1987, Clinical and experimental immunology.

[78]  J. Levy,et al.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. , 1986, Science.

[79]  F. Walshe The structure of medicine. , 1948, Lancet.

[80]  M. Clerici,et al.  A TH1-->TH2 switch is a critical step in the etiology of HIV infection. , 1993, Immunology today.

[81]  J. Mellors,et al.  Tumor necrosis factor-alpha/cachectin enhances human immunodeficiency virus type 1 replication in primary macrophages. , 1991, The Journal of infectious diseases.